Arisaph Pharmaceuticals

Arisaph Pharmaceuticals is focused on the development of therapies for cancer, cardiovascular disease, and diabetes.

Arisaph Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing therapies for cancer, cardiovascular disease, and diabetes. Its products include dipeptidylpeptidase IV inhibitors, stable GLP-1 agonists, HDL modulators and plaque reducers, and tumor activated pro-soft drugs. Arisaph Pharmaceuticals, Inc. was formerly known as Triad Pharmaceuticals, Inc. and changed its name to Arisaph Pharmaceuticals, Inc. in November 2005. The company was incorporated in 1999 and is based in Boston, Massachusetts.